1. Post-embolism syndrome
The vast majority (>90%) of THACE patients after surgery experience anorexia, gastrointestinal discomfort, nausea, vomiting (12.3%), fever (70.6%~96%, 38~39℃), lasting for 1-2 weeks, or even 1 month. Right upper quadrant abdominal pain (46%) and paralytic intestinal obstruction may also occur. Severe cases may exhibit pale complexion, slow pulse, cold extremities, excessive sweating, and a drop in blood pressure immediately or shortly after embolism. Generally, symptomatic treatment is given, which can gradually restore normalcy.
2. Complications related to chemotherapy drugs
1. Myocardial lesions caused by cardiac toxicity
Commonly seen after THACE surgery with anthracycline chemotherapy drugs, especially doxorubicin (ADM, 30% with a total dose of 600mg/m2, about 50% with >1000mg/m2), severe cases may develop heart failure. A small number of patients using high doses of CTX and 5-FU may also experience myocardial injury. Once myocardial injury occurs, the first measure should be bed rest, low-sodium diet, and electrocardiographic monitoring, timely administration of myocardial nutrition drugs, and continuous low-flow oxygen inhalation.
2, Suppression of bone marrow hematopoietic function
The hematopoietic function of the bone marrow is suppressed after interventional chemotherapy, manifested as leukopenia, and platelets and red blood cells are also affected to varying degrees, with severe cases showing a decrease in whole blood. It is common after the application of mitomycin C (MMC), ADM, cisplatin (CDDP), or carboplatin (BP).
3, Gastrointestinal toxicity reaction
The incidence rate of mucosal damage of the gastrointestinal tract is, manifested as discomfort in the stomach, nausea, vomiting, stomatitis, and diarrhea, which is due to some chemotherapy drugs or embolic agents entering or refluxing into the gastroduodenal artery during the embolization process. It is common during the operation of THACE using fluorouracil (5-FU), CDDP, MMC, and ADM, and is related to the dose. Antacids and antiemetics (such as famotidine and metoclopramide) can often alleviate the symptoms, and it is necessary to stop chemotherapy immediately and replenish fluid to regulate the balance of water and electrolytes.
Three, Complications related to instrument operation
1, Intimal injury and stripping of the hepatic artery
The incidence rate is as high as 34.3% (by procedure), and also reaches 1.5% (by case). High-risk factors:
(1) Damage to the normal structure of the arterial wall, such as atherosclerosis.
(2) Abnormal curvature or course of the artery, such as atherosclerosis or pressure from a large liver tumor.
(3) Arterial wall injury due to excessive roughness or repeated insertion of guide wires/catheters during catheterization; most have no corresponding clinical symptoms.
2, Liver artery stenosis or occlusion
The incidence rate is 2.9% to 7.7% (by case) or 0.4% (by procedure). High-risk factors:
(1) Same as 'intimal injury and stripping of the hepatic artery'.
(2) Liver artery with small development.
(3) Spasm and occlusion of the blood vessel due to stimulation by interventional therapy, if the operation is continued forcibly, it may cause vascular injury and permanent occlusion. Those with any of the three high-risk factors are prone to thrombosis in the hepatic artery after THACE surgery, which may lead to stenosis or occlusion of the lumen.
Clinical symptoms are usually not obvious. The main preventive measures are the same as those for intimal injury and stripping of the hepatic artery.
3, Liver artery puncture and pseudo-aneurysm formation
The incidence rate is 0.17% to 0.35%. High-risk factors:
(1) Same as 'intimal injury and stripping of the hepatic artery'.
(2) Failure of the high-pressure injector to inject pressure, especially when the end hole of the catheter is tightly attached to the arterial wall.
Clinical manifestations: There are usually no obvious clinical symptoms; if the large artery branch is pierced, abdominal pain, hemorrhagic shock, and other symptoms may occur. Diagnosis is not very difficult. The main preventive measures are the same as mentioned above.
4, Multiple hepatic intrapulmonary aneurysms
The incidence rate is 0.26% to 0.38%. The cause is controversial, and most scholars believe it is related to the following reasons
(1) Stimulation from guide wires, catheters, chemotherapy drugs, and embolic agents;
(2) Inflammation and increased fragility of the vascular wall after embolization of the blood supply branch; most have no clinical symptoms.
Prevention: Try to use microcatheters and superselective catheterization. This phenomenon usually disappears within 3 to 12 months after THACE surgery.
Four, Complications of the Liver and Bile Duct System
1, Acute liver failure
Most patients with primary liver cancer are accompanied by liver cirrhosis and liver dysfunction, and the chemotherapy drugs used in THACE not only have a great killing effect on liver cancer cells but also damage normal liver cells. If the perfusion dose is too large or / and non-selective catheter over-chemotherapy embolization, it will cause serious damage to normal liver tissue and lead to acute liver failure. In addition, it is also the final outcome of other serious complications after THACE.
The incidence rate is 0.3% to 1% (by case). High-risk factors include:
(1) Those with poor liver reserve function before interventional surgery, such as Child B, C grade or Okuda II, III grade, lactate dehydrogenase greater than 425U/L, aspartate aminotransferase >100mL, serum bilirubin >2mg/dL, liver tumor >50%.
(2) Those with main portal vein or primary branch cancer thrombus.
(3) Those with significant portal hypertension caused by liver cirrhosis or / and portal vein cancer thrombus.
(4) Those with large tumors and without superselective catheter injection of hyperosmotic iodized oil suspension chemotherapy drugs.
Clinically, rapid deepening of jaundice, persistent nausea and vomiting, liver odor, significant reduction in liver dullness, toxic megacolon, ascites, and bleeding of the skin and mucous membranes can occur quickly; followed by acute renal insufficiency (hepatorenal syndrome) and varying degrees of hepatic encephalopathy leading to coma. Most patients die within a few days due to liver and kidney failure or severe bleeding.
The prognosis of such complications is extremely poor, with a mortality rate of up to 50% to 90%.
2, Liver infarction (necrosis)
The injection of a large amount of iodized oil suspension chemotherapy drug (or reflux into) the normal liver tissue supplying the hepatic artery branches around the tumor can cause ischemia of the liver tissue in the supplying area, which may lead to infarction (necrosis) of the liver tissue. The incidence rate is 0.1% to 0.2% (by case). High-risk factors include:
(1) Those with main portal vein obstruction (tumor invasion or cancer thrombus).
(2) Those with significant hepatic artery-pulmonary vein shunting (APVS).
(3) Those who have not performed superselective catheter injection of hyperosmotic iodized oil suspension chemotherapy drugs.
(4) Those who have applied liquid embolic agents (such as anhydrous alcohol) or small diameter (50μm) particle embolic agents. Clinical manifestations include upper right abdominal pain, jaundice, fever (especially in secondary infections), liver function damage, or acute liver failure. CT and MRI scans can clearly show the range, degree, and nature (hemorrhagic or non-hemorrhagic infarction) of liver infarction after THACE, as well as the local liver atrophy caused by it.